Analysts Anticipate Brainstorm Cell Therapeutics (BCLI) to Announce -$0.14 Earnings Per Share

Brokerages forecast that Brainstorm Cell Therapeutics (NASDAQ:BCLI) will announce earnings per share of ($0.14) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Brainstorm Cell Therapeutics’ earnings. Brainstorm Cell Therapeutics reported earnings per share of ($0.10) in the same quarter last year, which would indicate a negative year-over-year growth rate of 40%. The company is scheduled to report its next earnings report on Monday, May 21st.

On average, analysts expect that Brainstorm Cell Therapeutics will report full-year earnings of ($0.66) per share for the current fiscal year. For the next fiscal year, analysts forecast that the company will report earnings of ($0.73) per share. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Brainstorm Cell Therapeutics.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last released its quarterly earnings data on Thursday, March 8th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.11.

Several research firms have recently issued reports on BCLI. Maxim Group set a $9.00 price objective on shares of Brainstorm Cell Therapeutics and gave the company a “buy” rating in a research report on Thursday, March 8th. ValuEngine upgraded shares of Brainstorm Cell Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Clearline Capital LP bought a new stake in Brainstorm Cell Therapeutics in the fourth quarter worth $208,000. Deutsche Bank AG increased its position in Brainstorm Cell Therapeutics by 330.0% in the fourth quarter. Deutsche Bank AG now owns 98,590 shares of the biotechnology company’s stock worth $386,000 after purchasing an additional 75,664 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in Brainstorm Cell Therapeutics by 396.9% in the fourth quarter. Renaissance Technologies LLC now owns 114,550 shares of the biotechnology company’s stock worth $449,000 after purchasing an additional 91,495 shares during the last quarter. Institutional investors own 9.55% of the company’s stock.

Shares of Brainstorm Cell Therapeutics stock traded down $0.07 on Monday, hitting $3.38. 28,872 shares of the company traded hands, compared to its average volume of 60,034. The stock has a market cap of $65.79, a P/E ratio of -13.00 and a beta of 1.86. Brainstorm Cell Therapeutics has a 52 week low of $2.88 and a 52 week high of $5.18.

WARNING: This story was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.

Get a free copy of the Zacks research report on Brainstorm Cell Therapeutics (BCLI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply